Home › Compare › CGPVF vs ABBV
CGPVF yields 1.49% · ABBV yields 3.06%● Live data
📍 ABBV pulled ahead of the other in Year 1
Combined, CGPVF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of CGPVF + ABBV for your $10,000?
Viridien engages in the provision of data, products, services, and solutions in Earth science, data science, sensing, and monitoring in North America, Latin America, the Central and South Americas, Europe, Africa, the Middle East, and the Asia Pacific. It operates through two segments: Data, Digital & Energy Transition (DDE); and Sensing & Monitoring (SMO). The DDE segments engages in the developing and licensing Earth data seismic surveys; processing and imaging seismic data; sale of seismic data processing software under the Geovation brand; provision of geoscience and petroleum engineering consulting services; and collecting, developing, and licensing geological data. The SMO segment is involved in the design, engineering, and manufacturing of seismic equipment for the land and marine seismic data acquisition, including seismic recording equipment, software, and seismic sources for land vibrators or marine sources, and sensing and monitoring equipment and solutions under the Sercel, Metrolog, GRC, DeRegt, and Geocomp brand names. This segment also provides customer support services, such as training. It provides its solutions for natural resources, environmental, infrastructure, energy transition, and digital applications. The company was formerly known as CGG and changed its name to Viridien in May 2024. Viridien was incorporated in 1931 and is headquartered in Massy, France.
Full CGPVF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.